A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Clinical trial NCT02107703 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02107703
- Sponsor
- Eli Lilly and Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-22
- Primary completion
- 2017-02-14
- Enrollment
- 669
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.